###begin article-title 0
###xml 78 82 78 82 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
Transcriptional Profiling of Non-Small Cell Lung Cancer Cells with Activating EGFR Somatic Mutations
###end article-title 0
###begin p 1
Conceived and designed the experiments: JK KC. Performed the experiments: KC NF. Analyzed the data: JK CC KC DS. Contributed reagents/materials/analysis tools: JK. Wrote the paper: JK CC KC.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
###xml 32 64 32 64 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">epidermal growth factor receptor</italic>
###xml 66 70 66 70 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
Activating somatic mutations in epidermal growth factor receptor (EGFR) confer unique biologic features to non-small cell lung cancer (NSCLC) cells, but the transcriptional mediators of EGFR in this subgroup of NSCLC have not been fully elucidated.
###end p 3
###begin title 4
Methodology/Principal Findings
###end title 4
###begin p 5
###xml 144 148 144 148 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 340 344 340 344 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 601 605 597 601 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 931 936 927 932 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PTGS2</italic>
###xml 941 946 937 942 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EphA2</italic>
###xml 990 994 986 990 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 731 739 <span type="species:ncbi:9606">patients</span>
Here we used genetic and pharmacologic approaches to elucidate the transcriptomes of NSCLC cell lines. We transcriptionally profiled a panel of EGFR-mutant and -wild-type NSCLC cell lines cultured in the presence or absence of an EGFR tyrosine kinase inhibitor. Hierarchical analysis revealed that the cell lines segregated on the basis of EGFR mutational status (mutant versus wild-type), and expression signatures were identified by supervised analysis that distinguished the cell lines based on mutational status (wild-type versus mutant) and type of mutation (L858R versus Delta746-750). Using an EGFR mutation-specific expression signature as a probe, we mined the gene expression profiles of two independent cohorts of NSCLC patients and found the signature in a subset. EGFR tyrosine kinase inhibitor treatment regulated the expression of multiple genes, and pharmacologic inhibition of the protein products of two of them (PTGS2 and EphA2) inhibited anchorage-independent growth in EGFR-mutant NSCLC cells.
###end p 5
###begin title 6
Conclusions/Significance
###end title 6
###begin p 7
###xml 56 60 56 60 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
We have elucidated genes not previously associated with EGFR-mutant NSCLC, two of which enhanced the clonogenicity of these cells, distinguishing these mediators from others previously shown to maintain cell survival. These findings have potential clinical relevance given the availability of pharmacologic tools to inhibit the protein products of these genes.
###end p 7
###begin title 8
Introduction
###end title 8
###begin p 9
###xml 198 201 198 201 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001226-Lynch1">[1]</xref>
###xml 202 205 202 205 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001226-Pao1">[3]</xref>
###xml 271 275 271 275 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 324 327 324 327 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001226-Lynch1">[1]</xref>
###xml 328 331 328 331 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001226-Pao1">[3]</xref>
###xml 523 526 519 522 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001226-Lynch1">[1]</xref>
###xml 527 530 523 526 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001226-Pao1">[3]</xref>
###xml 599 603 595 599 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 799 803 795 799 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 803 806 799 802 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001226-Sato1">[6]</xref>
###xml 860 864 856 860 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 925 929 921 925 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 1014 1018 1010 1014 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 149 157 <span type="species:ncbi:9606">patients</span>
###xml 232 240 <span type="species:ncbi:9606">patients</span>
###xml 532 537 <span type="species:ncbi:10090">Mouse</span>
###xml 706 711 <span type="species:ncbi:9606">human</span>
###xml 957 962 <span type="species:ncbi:9606">human</span>
###xml 964 970 <span type="species:ncbi:10090">murine</span>
Treatment with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) leads to rapid and sustained tumor shrinkage in a subset of patients with non-small cell lung cancer (NSCLC) [1]-[3]. The tumor cells in these patients have somatic mutations in the EGFR kinase domain that constitutively activate EGFR [1]-[3]. The activating mutations identified thus far cluster in the region that encodes the kinase domain (exons 18-21) and are most frequently either Delta746-750 deletion or L858R point mutations [1]-[3]. Mouse models constructed to investigate the oncogenicity of mutant EGFR develop invasive lung adenocarcinomas that regress after treatment with EGFR TKIs [4;5]. Immortalized human bronchial epithelial cells acquire malignant properties after transfection with mutant EGFR[6]. Treatment with EGFR TKIs induces apoptosis of these EGFR-transfected cells and NSCLC cells with somatic mutations in EGFR [7;8]. Thus, evidence from human, murine, and cellular models indicates that mutant EGFR is oncogenic and confers dependence on EGFR for NSCLC cell survival.
###end p 9
###begin p 10
###xml 22 26 22 26 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 283 286 283 286 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001226-Carey1">[9]</xref>
###xml 287 291 287 291 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001226-Yun1">[11]</xref>
###xml 293 297 293 297 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 472 475 472 475 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001226-Fujimoto1">[8]</xref>
###xml 795 799 795 799 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001226-Engelman1">[12]</xref>
###xml 907 911 907 911 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
The potency of mutant EGFR as an oncogene is supported by evidence that its biochemical properties differ sharply from those of wild-type EGFR. The EGFR kinase domain is constitutively activated by the somatic mutations, and it displays enhanced binding and sensitivity to EGFR TKIs [9]-[11]. EGFR-mutant NSCLC cells typically express high levels of EGFR and its dimeric partners ErbB2 and ErbB3 and multiple ErbB ligands, all of which potentiate EGFR-dependent signaling [8]. Multiple signaling pathways are constitutively activated in these cells, some of which have been shown to promote cell survival. For example, EGFR forms a heterodimeric complex with ErbB3, which binds to and directly activates phosphatidylinositol 3-kinase and maintains cell survival through AKT-dependent mechanisms [12]. Other pro-survival signals are mediated through Src family kinases, which are constitutively activated in EGFR-mutant NSCLC cells [13;14].
###end p 10
###begin p 11
###xml 152 156 152 156 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 467 471 467 471 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 521 525 521 525 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 828 832 828 832 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 954 962 <span type="species:ncbi:9606">patients</span>
In contrast to the advances made in elucidating mediators of cell survival, less progress has been made in understanding the mechanisms by which mutant EGFR confers other neoplastic properties, such as the ability to migrate, invade, proliferate in an anchorage-independent manner, and promote angiogenesis. Here we sought to identify those mediators by interrogating the transcriptomes of a panel of NSCLC cell lines that have been characterized for the presence of EGFR mutations. We found a transcriptional profile of EGFR-mutant NSCLC cells that included genes not previously been known to be EGFR-dependent. Although the range of cellular functions attributed to these genes is broad, many of them are linked through known or predicted protein interaction networks. In conclusion, the transcriptional profile identified in EGFR-mutant NSCLC cells has informed us about biologic processes and potential therapeutic targets that could be effective in patients with this disease.
###end p 11
###begin title 12
Results
###end title 12
###begin title 13
Transcriptional Analysis of NSCLC Cell Lines
###end title 13
###begin p 14
###xml 43 50 43 50 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0001226-t001">Table 1</xref>
###xml 119 123 119 123 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 194 197 194 197 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ras</italic>
###xml 274 278 274 278 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 554 558 550 554 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 611 616 607 612 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">N-ras</italic>
###xml 640 645 636 641 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">K-ras</italic>
###xml 475 485 <span type="species:ncbi:111938">gatekeeper</span>
We used a panel of eight NSCLC cell lines (Table 1) that had been characterized for the presence or absence of somatic EGFR mutations (five cell lines with such mutations and three without) and Ras mutations (two cell lines with such mutations and six without). Of the five EGFR-mutant cell lines, three had exon 19 deletion mutations (Delta746-750) (HCC827, HCC2279, H4006), one had an exon 21 point mutation (L858R) (H3255), and one had L858R in combination with the T790M gatekeeper mutation that confers resistance to EGFR TKIs (H1975). Of the three EGFR-wild-type cell lines, one had a somatic mutation in N-ras (H1299), and one had a K-ras mutation (H460). RNA was extracted and prepared from cells after they had been cultured for 2 h at 70% confluence in the presence or absence of the EGFR TKI gefitinib (1.0 microM). This duration of TKI treatment was chosen to identify the earliest transcriptional events induced by EGFR inhibition and to minimize the detection of gene expression changes due to apoptosis. The RNA was subjected to Affymetrix gene expression profiling, and the profiles were examined for differences in gene expression at baseline and after TKI treatment.
###end p 14
###begin title 15
Characteristics of NSCLC Cell Lines
###end title 15
###begin p 16
###xml 32 35 32 35 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">50 </sub>
###xml 78 81 78 81 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">50 </sub>
Abbreviations: WT, wild-type; IC50 , 50% inhibitory concentration Gefitinib IC50 values have been reported (Fujimoto et al., 2005).
###end p 16
###begin p 17
###xml 18 22 18 22 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 182 186 182 186 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 257 263 257 263 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001226-g001">Fig. 1</xref>
###xml 369 375 365 371 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001226-g001">Fig. 1</xref>
###xml 476 480 472 476 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 530 531 526 527 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 595 600 591 596 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR-</italic>
###xml 676 683 672 679 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0001226.s001">File S1</xref>
###xml 733 734 729 730 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</italic>
###xml 727 734 723 730 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001226-g002">Fig. 2<italic>A</italic></xref>
###xml 862 866 858 862 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 901 908 897 904 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0001226.s002">File S2</xref>
We first examined EGFR mutational status as a classifier of the transcriptional profiles. Hierarchical analysis revealed clustering of the cell lines based on mutational status; the EGFR-mutant cells lines clearly segregated from the -wild-type cell lines (Fig. 1). However, there was no clear separation between the two types of mutations (L858R versus Delta746-750) (Fig. 1). By supervised analysis using specific criteria (at least a 2.0-fold increase or a 50% decrease in EGFR-mutant cell lines relative to that of wild-type, P<0.05), 194 unique genes were identified that distinguished the EGFR-mutant cell lines from the -wild-type cell lines. These genes are listed in File S1 and illustrated in a clustered heat map in Fig. 2A. We examined 29 of the 194 genes by quantitative PCR and validated that 19 (68%) of them were differentially expressed between EGFR-mutant and -wild-type cell lines (File S2).
###end p 17
###begin title 18
Hierarchical analysis of gene expression profiles in eight NSCLC cell lines.
###end title 18
###begin p 19
###xml 149 153 149 153 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
Dendrogram illustrating the relatedness of expression profiles from cell lines treated with (+) or without (-) gefitinib. The presence or absence of EGFR somatic mutations and the type of mutations, including L858R point mutation (P) or Delta746-750 deletion mutation (D), are indicated. WT, wild-type.
###end p 19
###begin title 20
###xml 27 31 27 31 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
Identification of a mutant EGFR gene expression profile.
###end title 20
###begin p 21
###xml 0 3 0 3 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(A)</italic>
###xml 44 48 44 48 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 183 186 183 186 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(B)</italic>
###xml 262 265 262 265 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(D)</italic>
###xml 407 408 407 408 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</italic>
###xml 489 493 489 493 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 515 516 515 516 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 642 643 642 643 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E</italic>
###xml 711 715 711 715 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 739 743 739 743 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 211 219 <span type="species:ncbi:9606">patients</span>
###xml 248 256 <span type="species:ncbi:9606">patients</span>
###xml 421 429 <span type="species:ncbi:9606">patients</span>
(A) A 194-gene signature that distinguishes EGFR-wild-type (WT) from -mutant NSCLC cell lines (treated with [+] or without [-] gefitinib) is aligned with the expression profiles from (B) the Michigan cohort (86 patients) and the Harvard cohort (84 patients) and (D) MCF-7 cells transfected with the indicated genes. A list of the genes that overlapped in all three data sets is indicated on the far right. (C) Numbers of patients in the Michigan and Harvard cohorts manifesting the mutant EGFR expression patterns (P<0.05, Pearson's correlation), along with the number manifesting a randomly generated pattern (SD based on 100 simulations). (E) Venn diagram illustrating the overlap between signatures from the EGFR-mutant NSCLC cells and EGFR-transfected MCF-7 cells.
###end p 21
###begin title 22
###xml 29 33 29 33 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 58 66 <span type="species:ncbi:9606">Patients</span>
Identification of the Mutant EGFR Signature in Cohorts of Patients with NSCLC
###end title 22
###begin p 23
###xml 708 712 708 712 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 748 749 748 749 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</italic>
###xml 742 749 742 749 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001226-g002">Fig. 2<italic>B</italic></xref>
###xml 125 133 <span type="species:ncbi:9606">patients</span>
###xml 478 483 <span type="species:ncbi:9606">human</span>
We next queried publicly available gene expression databases of tumor biopsy samples derived from two independent cohorts of patients with NSCLC from the United States (15, 16) to determine whether a subset of tumors expressed this genetic signature. Of the 194 genes, 102 (53%) were represented on the profiling platform used in the Harvard cohort, and 65 (34%) were represented in the Michigan cohort. Based on a heat map representation of their gene expression patterns, the human lung tumors were heterogeneous in their expression patterns; however, a subset of tumors (9 of 84 [11%] in the Harvard cohort and 10 of 86 [12%] in the Michigan cohort) exhibited an expression pattern similar to that of the EGFR-mutant NSCLC gene signature (Fig. 2B).
###end p 23
###begin p 24
###xml 189 190 189 190 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 227 231 227 231 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 505 509 505 509 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 610 611 610 611 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 735 742 735 742 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001226-g002">Fig. 2C</xref>
To determine whether the similarities observed by heat map analysis reached statistical significance, parameters were created that defined similarity as a positive Pearson's correlation of P<0.05 (two-sided) between the mutant EGFR signature pattern and the gene expression values of the tumor, taking into account both the over- and under-expressed genes in the signature. By this definition, tumors manifesting this signature would recapitulate the patterns of over-and under-expression observed in the EGFR-mutant cell lines. The incidence of tumors manifesting the signature was statistically significant (P<0.01 for each cohort) based on simulations using 100 randomly selected gene signatures generated from each of the cohorts (Fig. 2C).
###end p 24
###begin p 25
###xml 13 17 13 17 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 115 120 115 120 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">K-ras</italic>
###xml 278 282 278 282 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 287 292 287 292 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">K-ras</italic>
###xml 325 329 325 329 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001226-Riely1">[17]</xref>
###xml 536 540 536 540 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001226-Riely1">[17]</xref>
###xml 629 634 629 634 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">K-ras</italic>
###xml 667 671 667 671 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 738 743 738 743 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">K-ras</italic>
###xml 805 809 805 809 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 832 836 832 836 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B, P</italic>
###xml 826 836 826 836 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001226-g002">Fig. 2<italic>B, P</italic></xref>
###xml 848 849 848 849 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 1020 1024 1020 1024 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 57 64 <span type="species:ncbi:9606">patient</span>
Although the EGFR mutational status of tumors from these patient cohorts has, to our knowledge, not been reported, K-ras (codons 12, 13, or 61) is known to be mutated in 29% and 45% of the tumors from the Harvard and Michigan cohorts, respectively [15;16]. Somatic mutations in EGFR and K-ras are mutually exclusive in NSCLC [17], which has led investigators to hypothesize that these events are genetically redundant and that a change in both genes does not confer a further advantage when these events occur together in the same cell [17]. We postulated that, if these somatic events are genetically redundant, then having the K-ras mutation will confer the mutant EGFR transcriptional profile. Consistent with this idea, we noted that K-ras mutational status correlated, albeit weakly, with the mutant EGFR gene signature (Fig. 2B, P = 0.07 and P = 0.04 in the Harvard and Michigan cohorts, respectively, by Wilcoxon rank-sum tests of the cohort profiles ordered by average expression of genes that were increased in EGFR-mutant cell lines).
###end p 25
###begin title 26
###xml 7 11 7 11 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
Mutant EGFR Signature Enriched with EGFR-Dependent Genes
###end title 26
###begin p 27
###xml 249 253 249 253 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Raf1</italic>
###xml 255 259 255 259 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MEK1</italic>
###xml 261 266 261 266 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ErbB2</italic>
###xml 286 290 286 290 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 340 344 340 344 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001226-Creighton1">[18]</xref>
###xml 407 411 407 411 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 440 444 440 444 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 496 500 496 500 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 851 855 851 855 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 899 900 899 900 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">D</italic>
###xml 893 900 893 900 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001226-g002">Fig. 2<italic>D</italic></xref>
To investigate whether any of the genes in the 194-gene signature were regulated in an EGFR-dependent manner, we queried a publicly available database of MCF-7 breast cancer cells that had been stably transfected with constitutively active kinases (Raf1, MEK1, ErbB2) or with wild-type EGFR, which was activated by short-term EGF treatment [18]. We investigated the overlap between the gene signatures from EGFR-transfected MCF-7 cells and EGFR-mutant NSCLC cells. Of the 194 genes in the mutant EGFR signature, 139 (72%) were represented on the profiling platform for the MCF-7 cell transfectants (11079 genes in all were represented in both the MCF-7 and NSCLC datasets). Analysis of these 139 genes revealed that subsets of the genes that were increased in MCF-7 cells because of MEK, Raf1, or EGFR transfection overlapped with those in the mutant EGFR expression signature in NSCLC cells (Fig. 2D).
###end p 27
###begin p 28
###xml 82 86 82 86 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 136 137 136 137 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 146 150 146 150 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 224 225 224 225 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 270 271 270 271 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E</italic>
###xml 264 271 264 271 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001226-g002">Fig. 2<italic>E</italic></xref>
###xml 424 428 424 428 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 457 461 457 461 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 572 573 572 573 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 590 591 590 591 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 636 640 636 640 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 769 771 769 771 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P&lt;</italic>
###xml 880 884 880 884 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 929 933 929 933 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
Of the 119 genes that were both represented in the MCF-7 dataset and increased in EGFR-mutant NSCLC cells, 44 (31%) were increased with P<0.05 in EGFR-transfected MCF-7 cells, which represented a highly significant overlap (P<1E-12, one-sided Fisher's exact test, Fig. 2E). By chance, 14 of the 119 genes would be expected to overlap, indicating that the amount of overlap we observed exceeded what would be expected if the EGFR-transfected MCF-7 cells and EGFR-mutant NSCLC cells nothing biologically in common with each other. When we used a more stringent cut point of P<0.01 instead of P<0.05 to define genes that were increased in EGFR-transfected MCF-7 cells (576 genes in all), 28 overlapped with the mutant EGFR NSCLC signature (chance expected of seven genes, P<1E-10, one-sided Fisher's exact test). We concluded that, based on its commonalities with the signature from EGFR-transfected MCF-7 cells, the signature from EGFR-mutant NSCLC cells was enriched for genes transcriptionally up-regulated by EGFR.
###end p 28
###begin title 29
###xml 18 23 18 23 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PTGS2</italic>
Identification of PTGS2 as a gene required for anchorage-independent growth
###end title 29
###begin p 30
###xml 48 52 48 52 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 181 189 181 189 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0001226.s003">Files S3</xref>
###xml 194 196 194 196 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0001226.s004">S4</xref>
###xml 437 447 437 447 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TGFA, AREG</italic>
###xml 453 457 453 457 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EREG</italic>
###xml 478 483 478 483 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PTGS2</italic>
###xml 530 537 530 537 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CX3CL1)</italic>
###xml 580 628 580 628 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TRIB2, MET, MYLK, STK39, ACVR1, TAOK3, and IFIH1</italic>
###xml 653 683 653 683 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PTPN22, DUSP10, PPAP2B, PTPRR,</italic>
###xml 688 693 688 693 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PTPRE</italic>
###xml 717 722 717 722 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SGPP2</italic>
###xml 745 767 745 767 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CEACAM6, ITGAV, PCDH7,</italic>
###xml 772 777 772 777 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">THBS1</italic>
###xml 814 821 814 821 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S100A14</italic>
###xml 826 833 826 833 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S100A16</italic>
The genes that were differentially expressed in EGFR-mutant NSCLC cell lines fell into a broad range of functional classes (categorized in the Gene Ontology Molecular Functions, ) (Files S3 and S4). The categories with highest representation were signal transduction, metabolism, immune response, ion transport, and cell cycle and proliferation. Genes in these categories that were highly expressed included those encoding ErbB ligands (TGFA, AREG, and EREG), cyclooxygenase-2 (PTGS2), a ligand for the CX3CR1 chemokine receptor (CX3CL1), intracellular and transmembrane kinases (TRIB2, MET, MYLK, STK39, ACVR1, TAOK3, and IFIH1), protein phosphatases (PTPN22, DUSP10, PPAP2B, PTPRR, and PTPRE), a lipid phosphatase (SGPP2), adhesion molecules (CEACAM6, ITGAV, PCDH7, and THBS1), and calcium ion-binding proteins (S100A14 and S100A16).
###end p 30
###begin p 31
###xml 492 496 492 496 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001226-Rhodes1">[19]</xref>
###xml 685 689 685 689 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001226-Jeong1">[20]</xref>
###xml 590 595 <span type="species:ncbi:4932">yeast</span>
To examine whether these differentially expressed genes, which have disparate biologic functions, were part of one or more signal transduction networks, we analyzed their positions within known or predicted global protein interaction networks (interactomes) using the HiMAP software program (). Interactomes identified by this approach are organized into a series of modular structures characterized by centrally-located nodes (called hubs) that have multiple connections with other proteins [19]. Although this approach is purely exploratory and carries no statistical weight, findings in yeast show that centrality in a protein interactome predicts a protein's biological importance [20].
###end p 31
###begin p 32
###xml 202 208 202 208 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001226-g003">Fig. 3</xref>
###xml 287 335 285 333 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CD44, MET, IRS1, GRB10, ITGA2, PTGS2, and THBS1,</italic>
###xml 374 378 372 376 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
Of the 194 differentially expressed genes, 118 had been annotated in Gene Ontology, of which 102 were included in the HiMAP software program (19). Of those 102 genes, 52 mapped within a single network (Fig. 3). The hubs in the network with the highest numbers of links (>/= 10) included CD44, MET, IRS1, GRB10, ITGA2, PTGS2, and THBS1, all of which were highly expressed in EGFR-mutant NSCLC cells, indicating that some of the differentially expressed genes were at central positions of this signaling network.
###end p 32
###begin title 33
Interactome of genes in the mutant EGFR expression signature.
###end title 33
###begin p 34
Theoretical protein-protein physical and functional interaction map (interactome) was drawn using HiMAP software. Genes from the signature are indicated in red.
###end p 34
###begin p 35
###xml 34 39 34 39 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PTGS2</italic>
###xml 303 307 303 307 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001226-Williams1">[21]</xref>
###xml 346 350 346 350 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 699 705 691 697 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001226-g004">Fig. 4</xref>
In light of the centrality of the PTGS2 gene in the interactome network and the known importance of its gene product cyclooxygenase-2 (COX-2) in the survival and metastasis of cancer cells and its potential clinical impact given the availability of pharmacologic tools to inhibit its enzymatic function [21], we sought to investigate its role in EGFR-mutant NSCLC cells. We examined whether the cyclooxygenase-2 inhibitor celecoxib abrogated the ability of these cells to proliferate in monolayer cultures and to form colonies in soft agar. Using celecoxib at low doses (0.5 microM and 1.0 microM) to minimize nonspecific effects, colony formation in soft agar decreased in a dose-dependent manner (Fig. 4), whereas proliferation in monolayers did not change (data not shown).
###end p 35
###begin title 36
Cyclooxygenase-2 inhibition decreases NSCLC anchorage-independent growth.
###end title 36
###begin p 37
Representative images of colonies of NSCLC cell lines (upper panels) were quantified (lower panels) after growing them in soft agar in the presence or absence of celecoxib. Results are the means of at least three independent experiments.
###end p 37
###begin title 38
###xml 16 20 16 20 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
Cell Lines with EGFR Deletions and Point Mutations Have Distinct Expression Profiles
###end title 38
###begin p 39
###xml 20 24 20 24 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 157 161 157 161 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 473 476 473 476 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001226-Carey1">[9]</xref>
###xml 477 481 477 481 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001226-Yun1">[11]</xref>
###xml 590 596 590 596 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001226-g001">Fig. 1</xref>
###xml 799 800 799 800 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 872 876 872 876 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 921 925 921 925 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 1021 1028 1021 1028 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0001226.s005">File S5</xref>
###xml 1072 1078 1072 1078 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001226-g005">Fig. 5</xref>
###xml 1270 1277 1266 1273 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0001226.s006">File S6</xref>
###xml 1805 1812 1784 1791 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0001226.s007">File S7</xref>
###xml 6 14 <span type="species:ncbi:9606">patients</span>
Among patients with EGFR-mutant NSCLC, differences in survival duration and responsiveness to EGFR TKI treatment have been observed depending on the type of EGFR somatic mutation (exon 21 point mutations versus exon 19 deletions) [22;23], suggesting that these two types of somatic mutations confer distinct biologic properties to NSCLC cells. Supporting this possibility is evidence that these two types of somatic mutations confer distinct biochemical properties to EGFR [9]-[11]. Although hierarchical clustering did not segregate the two types of mutations into two distinct subgroups (Fig. 1), we hypothesized that supervised analysis would reveal transcriptional differences between the two types of mutations. Indeed, clear transcriptional differences were observed. Using specific criteria (P<0.01, at least two-fold change), we identified a 270-gene signature in EGFR-mutant cell lines (which was not present in EGFR-wild-type cell lines) that distinguished the two types of mutations. These genes are listed in File S5 and illustrated in a clustered heat map in Fig. 5. We examined 7 of the 270 genes by quantitative PCR and validated that 4 (57%) were differentially expressed between cell lines with L858R mutations versus those with Delta746-750 mutations (File S6). The 270-gene signature was analyzed for enrichment in specific gene functions as defined by the Gene Ontology Signature Database. L858R-mutant cells were enriched for genes in the cyclic AMP-dependent protein kinase- , protein phosphatase-2epsilon-, Ras-family member RAB3D-, and phospholipase-Cbeta1-dependent pathways, whereas the Delta746-750 mutants were enriched for genes in the CXC chemokine ligands (2 and 3)-, integrin alpha6-, guanylate binding proteins (1, 2, and 3)-, and interleukin-7 and 10-dependent pathways (File S7), demonstrating that the gene sets activated by the two mutation types are functionally distinct.
###end p 39
###begin title 40
###xml 53 57 53 57 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
Expression signature that distinguishes two types of EGFR mutations.
###end title 40
###begin p 41
###xml 32 36 32 36 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
A 194-gene signature present in EGFR-mutant but not EGFR-wild-type cell lines distinguishes L858R (P.M. [point mutation]) from Delta746-750 (deletion). Cells were treated with (+) or without (-) gefitinib. A partial list of the genes that are differentially expressed in the two groups is indicated on the right.
###end p 41
###begin title 42
Genes Regulated by EGFR TKI Treatment
###end title 42
###begin p 43
###xml 126 130 126 130 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 361 365 361 365 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001226-Riely1">[17]</xref>
###xml 392 393 392 393 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 518 525 518 525 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0001226.s008">File S8</xref>
###xml 758 765 758 765 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0001226.s009">File S9</xref>
###xml 855 884 855 884 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCNG2, CDKN1B, ID2, and KNTC2</italic>
###xml 951 956 951 956 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EphA2</italic>
###xml 994 1005 994 1005 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LIF, CCL20,</italic>
###xml 1010 1015 1010 1015 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IL17B</italic>
###xml 1041 1046 1041 1046 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FOXD1</italic>
###xml 1051 1057 1051 1057 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">POU1F1</italic>
###xml 1086 1091 1086 1091 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">DUSP4</italic>
###xml 1096 1101 1096 1101 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">DUSP6</italic>
To identify gene expression changes that preceded, and possibly contributed to, the biologic effects of EGFR TKI treatment on EGFR-mutant NSCLC cells, the cells were subjected to short-term treatment with gefitinib. As a negative control in this experiment, we used the TKI-resistant H1975 cells, which have a T790M mutation that blocks binding to the EGFR TKI [17]. Using specific criteria (P<0.05), we found that 54 genes were regulated by TKI exclusively in the TKI-sensitive cell lines (HCC827, H3255, and H4006) (File S8), none of which have, to our knowledge, been reported to be EGFR-dependent genes. Among these genes, we examined 14 by quantitative PCR and validated that 10 (71%) were differentially regulated in TKI-sensitive and resistant cells (File S9). Genes that increased in response to TKI included, among others, cell cycle regulators (CCNG2, CDKN1B, ID2, and KNTC2) and a ligand for EphA2 (EFNA1). Genes that decreased include the EphA2 receptor tyrosine kinase, cytokines (LIF, CCL20, and IL17B), transcription factors (FOXD1 and POU1F1), and protein phosphatases (DUSP4 and DUSP6).
###end p 43
###begin title 44
Reciprocal Regulation of EphA2 and EFNA1 is EGFR-Dependent
###end title 44
###begin p 45
###xml 436 439 436 439 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A&#8211;C</italic>
###xml 430 439 430 439 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001226-g006">Fig. 6<italic>A&#8211;C</italic></xref>
###xml 513 524 513 524 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A, E, and F</italic>
###xml 507 524 507 524 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001226-g007">Fig. 7<italic>A, E, and F</italic></xref>
###xml 613 614 613 614 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</italic>
###xml 607 614 607 614 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001226-g007">Fig. 7<italic>C</italic></xref>
###xml 736 737 736 737 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</italic>
###xml 730 737 730 737 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001226-g007">Fig. 7<italic>B</italic></xref>
###xml 1003 1004 1003 1004 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">F</italic>
###xml 997 1004 997 1004 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001226-g007">Fig. 7<italic>F</italic></xref>
In light of the importance of the EphA axis in tumorigenesis [24;25], we further investigated the effects of TKI treatment on the expression of EphA2, other EphA family members, and their ligand EFNA1. Quantitative PCR and western analysis confirmed that gefitinib reciprocally regulated the expression of EphA2 and its ligand EFNA1 in TKI-sensitive cell lines (HCC827, H4006, and H3255) but not in the TKI-resistant H1975 cells (Fig. 6A-C). EphA1, EphA5, and EphA6 did not change with gefitinib treatment (Fig. 7A, E, and F); EphA4 decreased in only a subset of TKI-sensitive cells (H4006 but not HCC827) (Fig. 7C); and EphA3 was inhibited in an EGFR-independent manner (indicated by the TKI-induced suppression in H1975 cells) (Fig. 7B). To more fully evaluate whether the suppression of EphA2 expression was EGFR-mediated, we examined the effect of another EGFR TKI, erlotinib, and found that it too inhibited EphA2 expression in TKI-sensitive cells, to an extent similar to that of gefitinib (Fig. 7F).
###end p 45
###begin title 46
Reciprocal regulation of EphA2 and EFNA1 in NSCLC cell lines.
###end title 46
###begin p 47
###xml 26 32 26 32 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(A, B)</italic>
###xml 54 57 54 57 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(C)</italic>
###xml 67 73 67 73 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(A, C)</italic>
###xml 84 90 84 90 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(B, C)</italic>
Quantitative PCR analysis (A, B) and western blotting (C) of EphA2 (A, C) and EFNA1 (B, C) in cell lines treated for 6 h with (+) or without (-) gefitinib. Quantitative PCR results represent the means of at least three independent experiments and were normalized based on expression of the housekeeping gene L32. The numbers under the bands are the results of densitometric analysis after normalizing for loading differences based on actin.
###end p 47
###begin title 48
EGFR TKI-induced changes in expression of EphA family members.
###end title 48
###begin p 49
Cells were treated for 6 h with vehicle, 1 microM gefitinib (A-E), or 1 microM erlotinib (F). RNA was extracted and subjected to quantitative PCR. Results represent the means of at least three independent experiments and were normalized based on L32 expression.
###end p 49
###begin title 50
EphA2 Activation is Required for Anchorage-Independent Growth
###end title 50
###begin p 51
###xml 225 226 225 226 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">c</sub>
###xml 354 358 354 358 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001226-Brantley1">[26]</xref>
###xml 464 470 464 470 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001226-g008">Fig. 8</xref>
We postulated that EphA2 signaling maintains neoplastic features of NSCLC cells and tested this hypothesis by treating HCC827 cells with EphA2-Fc, a recombinant peptide containing the EphA2 extracellular domain fused to the Fc fragment of IgG, which prevents the interaction of ephrin A ligands with endogenous EphA, effectively blocking EphA activation [26]. Relative to that of controls, EphA2-Fc-treated cells exhibited decreased colony formation in soft agar (Fig. 8) whereas their proliferation in monolayer cultures did not change (data not shown), indicating that EphA was required for the anchorage-independent proliferation of these cells.
###end p 51
###begin title 52
EphA2-Fc inhibits NSCLC anchorage-independent growth.
###end title 52
###begin p 53
Representative images of colonies of NSCLC cell lines (top) with quantification of colonies (bottom) after growth in soft agar in the presence or absence of EphA2-Fc. Results are the means of at least three independent experiments.
###end p 53
###begin title 54
Discussion
###end title 54
###begin p 55
###xml 45 49 45 49 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 152 156 152 156 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 258 262 258 262 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 558 563 558 563 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EphA2</italic>
###xml 568 573 568 573 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PTGS2</italic>
###xml 610 614 610 614 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 510 518 <span type="species:ncbi:9606">patients</span>
Here we report that NSCLC cells with somatic EGFR mutations have a unique transcriptional profile and that cell lines with the two most common types of EGFR mutations have clear transcriptional differences. By mining gene expression databases using a mutant EGFR-specific signature as a probe, we found that many of the genes in this expression signature were EGFR-dependent, converged into common networks on the basis of known or predicted protein interactomes, and were expressed in tumors from a subset of patients with NSCLC. Two genes were elucidated, EphA2 and PTGS2, that promoted the clonogenicity of EGFR-mutant NSCLC cells, which are of particular interest from a clinical standpoint because they can be inhibited pharmacologically.
###end p 55
###begin p 56
###xml 24 28 24 28 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 293 299 293 299 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PTGS2,</italic>
###xml 317 321 317 321 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EREG</italic>
###xml 326 331 326 331 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">AREG,</italic>
###xml 336 339 336 339 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Met</italic>
###xml 414 418 414 418 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 534 539 534 539 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PTGS2</italic>
###xml 705 709 705 709 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 734 738 734 738 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LY96</italic>
###xml 743 749 743 749 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CX3CL1</italic>
###xml 796 800 796 800 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LY96</italic>
###xml 1027 1031 1027 1031 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001226-Kobayashi1">[30]</xref>
###xml 1033 1039 1033 1039 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CX3CL1</italic>
###xml 1245 1252 1245 1252 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 1252 1256 1252 1256 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001226-Lavergne1">[31]</xref>
Genes within the mutant EGFR gene expression signature encode proteins with a diverse set of cellular functions. The influence of EGFR on this signature was demonstrated by its overlap with that of EGFR-transfected MCF-7 cells and the presence of known EGFR transcriptional targets, including PTGS2, the ErbB ligands EREG and AREG, and Met, a receptor tyrosine kinase that was recently reported to be activated in EGFR-mutant NSCLC cells and to promote TKI resistance in these cells [8;27-29]. Here we showed that the gene product of PTGS2, cyclooxygenase-2, has an important role, promoting anchorage-independent growth. This signature contained many genes not previously known to be highly expressed in EGFR-mutant NSCLC, including LY96 and CX3CL1, which have known immunomodulatory functions. LY96 encodes MD2, an accessory molecule required for the activation of toll-like receptor-4, which promotes cell survival and induces the secretion of immunosuppressive molecules that promote tumor evasion from immune surveillance [30]. CX3CL1 encodes a secreted protein called fractalkine that recruits CX3CR1-expressing natural killer and T lymphocytes to the tumor microenvironment, thereby promoting natural killer-dependent antitumor responses in vivo[31]. On the other hand, fractalkine has also demonstrated pro-metastatic properties based on evidence that it promotes tumor cell migration and enhances adhesion of tumor cells to endothelial cells [32;33].
###end p 56
###begin p 57
###xml 68 72 68 72 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 154 159 154 159 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EphA2</italic>
###xml 175 180 175 180 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EFNA1</italic>
###xml 344 349 344 349 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EFNA1</italic>
###xml 413 418 413 418 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EphA2</italic>
###xml 430 434 430 434 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001226-Macrae1">[25]</xref>
###xml 701 705 701 705 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001226-Macrae1">[25]</xref>
###xml 788 817 788 817 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCNG2, CDKN1B, ID2, and KNTC2</italic>
###xml 1153 1161 1153 1161 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CEACAM-6</italic>
###xml 1166 1171 1166 1171 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">DUSP6</italic>
###xml 1203 1207 1203 1207 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
To identify genes regulated in an EGFR-dependent manner, we treated EGFR-mutant NSCLC cells with gefitinib. Two of the genes identified by this approach, EphA2 and its ligand EFNA1, were regulated in a reciprocal fashion. Potentially mediating this effect of gefitinib, mitogen-activated protein kinase, a downstream effector of EGFR, inhibits EFNA1 expression, thereby relieving the EFNA1-induced suppression of EphA2 expression [25]. Moreover, we found that EphA2/EFNA1 interactions were required for the anchorage-independent growth of HCC827 cells, which corroborates findings from a previous study demonstrating that v-ErbB-dependent cellular transformation is attenuated by EphA2 ligand-binding [25]. Other genes we found to be regulated by gefitinib in TKI-sensitive cells include CCNG2, CDKN1B, ID2, and KNTC2, which are components of cell cycle regulatory pathways. Given that their expression changed before any biochemical evidence of proliferative arrest or apoptosis, these genes might be part of an anti-proliferative signaling program activated by gefitinib. Lastly, two of the genes that decreased in abundance with gefitinib treatment (CEACAM-6 and DUSP6) were also highly expressed in EGFR-mutant cells, suggesting that these genes are potentially important EGFR transcriptional targets in these cells.
###end p 57
###begin p 58
###xml 85 89 85 89 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 252 256 252 256 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 427 435 <span type="species:ncbi:9606">patients</span>
In summary, we have identified a transcriptome in NSCLC cells that elucidates mutant EGFR-induced gene expression changes and provides a transcriptional basis for the biologic differences observed in NSCLC with the two most commonly occurring types of EGFR mutations. Further analysis of these genes may inform us about biologic processes that can be used to identify intracellular targets of potential therapeutic benefit for patients with this disease.
###end p 58
###begin title 59
Materials and Methods
###end title 59
###begin title 60
Reagents
###end title 60
###begin p 61
###xml 146 152 <span type="species:ncbi:10090">murine</span>
###xml 235 242 <span type="species:ncbi:9986">rabbits</span>
###xml 315 326 <span type="species:ncbi:3704">horseradish</span>
###xml 350 355 <span type="species:ncbi:10090">mouse</span>
###xml 364 370 <span type="species:ncbi:9986">rabbit</span>
Gefitinib (Astra Zeneca Pharmaceuticals, Wilmington, DE) and erlotinib (OSI Pharmaceuticals, Melville, NY) were gifts. We purchased a recombinant murine EphA2-Fc chimera (R&D Systems, Minneapolis, MN), polyclonal antibodies derived in rabbits against EphA2 and EFNA1 (Santa Cruz Biotechnologies, Santa Cruz, CA), a horseradish peroxidase-linked anti-mouse and ant-rabbit secondary antibodies (Cell Signaling Biotechnology, Beverly, MA), and an antibody against beta-actin (Sigma-Aldrich, St. Louis, MO).
###end p 61
###begin title 62
Cell Lines
###end title 62
###begin p 63
###xml 135 136 135 136 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 243 249 <span type="species:ncbi:9913">bovine</span>
The NSCLC cell lines used in this study were purchased from the American Type Culture Collection (Manassas, VA) and were grown in 5% CO2 at 37degreesC in RPMI 1640 medium with high glucose (4.5 g/L; GIBCO-BRL, MD), supplemented with 10% fetal bovine serum (Hyclone, Logan, Utah).
###end p 63
###begin title 64
Gene Expression Profiling
###end title 64
###begin p 65
RNAs were isolated by using the RNeasy Mini Kit (Qiagen, Valencia, CA) and hybridized to Affimetrix U133+2.0 gene expression chips at the M.D. Anderson Cancer Center Microarray Core Facility (supported in part by grant CA #16672). dChip () (2005 version) was used to extract expression values for each probe set. Control probe sets and probe sets with suffixes "_s_at" and "_x_at" on their ID were excluded (because these probe sets may target more than one unique sequence), leaving 39,114 of 54,675 original probe sets for further analysis.
###end p 65
###begin title 66
Determination of differentially expressed genes
###end title 66
###begin p 67
###xml 11 12 11 12 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</italic>
###xml 122 126 122 126 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 221 222 221 222 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 341 342 341 342 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
Two-sample t tests (using log-transformed data) were used to determine significant differences in gene expression between EGFR-mutant and -wild-type NSCLC cell lines and between EGFR-transfected and parental MCF-7 cells (P values were two-sided). For the analysis of gefitinib treatment effects, a paired difference was calculated as the log2(gefitinib-treated/vehicle-treated).
###end p 67
###begin title 68
GO enrichment analysis
###end title 68
###begin p 69
###xml 177 181 177 181 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001226-Creighton2">[34]</xref>
###xml 558 559 558 559 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 568 569 568 569 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Q</italic>
###xml 656 661 656 661 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al</italic>
###xml 663 667 663 667 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001226-Storey1">[35]</xref>
Functional gene groups as defined by Gene Ontology (GO) annotation () were evaluated for enrichment within our own experimentally-derived gene sets. Essentially as described in [34], one-sided Fisher's exact tests were performed to assess whether or not genes in each GO functional group were over-represented in our gene set (the 16,172 genes represented by the 39,114 probe sets on the array were used as the reference population). Gene Ontology annotations were obtained from the NCBI's annotation file gene2go (). In addition to one-sided Fisher's exact P-values, Q-values were computed to account for multiple term testing, using the method by Storey et al. [35].
###end p 69
###begin title 70
HiMAP interactome analysis
###end title 70
###begin p 71
###xml 421 425 421 425 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001226-Salwinski1">[36]</xref>
###xml 201 206 <span type="species:ncbi:9606">Human</span>
Gene lists were imported into the HiMAP program () for protein-protein interaction network analysis. HiMAP (19) includes both experimentally-validated protein-protein interactions (as cataloged in the Human Protein Reference Database, or HPRD []), and predicted protein-protein interactions based on a probabilistic model integrating multiple factors, including interactome data from the Database of Interacting Proteins [36], protein domain data, genome-wide expression data, and functional annotation data from GO.
###end p 71
###begin title 72
Analysis of the EGFR mutation gene signature in additional profile datasets
###end title 72
###begin p 73
###xml 394 398 394 398 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 415 424 415 424 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001226-g002">Figure 2C</xref>
###xml 612 616 612 616 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 818 822 818 822 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 1153 1157 1153 1157 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 128 133 <span type="species:ncbi:9606">human</span>
###xml 351 356 <span type="species:ncbi:9606">human</span>
###xml 651 656 <span type="species:ncbi:9606">human</span>
###xml 949 954 <span type="species:ncbi:9606">human</span>
Expression values were visualized as color maps using the Cluster and Java TreeView programs [37; 38]. Expression values in the human lung adenocarcinoma datasets were transformed to standard deviations from the tumor mean. The set of profiles analyzed in the Harvard dataset were the same set as was analyzed in Beer et al. (15). For correlating the human NSCLC tumor profiles with the mutant EGFR gene signature (Figure 2C), +1 and -1 were used to represent each of the genes up and down, respectively, in the signature. The Pearson's correlation coefficient was computed based on the comparison of the mutant EGFR signature pattern to that of each human NSCLC tumor profile. In 100 separate simulation tests, a randomly generated gene signature (with the same number of up and down genes as there was in the mutant EGFR signature) was generated, and the Pearson's correlation was computed based on the comparison of this random signature to each human NSCLC tumor. In no single test did the number of tumors with significant positive correlations (p<0.05, two-sided) to the random pattern exceed the number that correlated positively with the mutant EGFR signature.
###end p 73
###begin p 74
###xml 511 512 511 512 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</italic>
###xml 105 110 <span type="species:ncbi:9606">human</span>
###xml 363 368 <span type="species:ncbi:9606">human</span>
The Entrez Gene identifier was used for mapping genes from the NSCLC cell line dataset to those from the human NSCLC tumor and MCF-7 profile datasets. Where a gene was represented several times on a given platform, an appropriate rule was used to select the "best" gene probe in a manner not biased towards detecting patterns of concordance between datasets (for human lung tumor datasets, the probe with the greatest variation; for MCF-7 datasets, the probe with the greatest difference in either direction by t test between EGFR and control). As an alternative approach to exclude potential bias, overlap between the NSCLC and MCF-7 data sets was examined using probes randomly selected from the NSCLC expression arrays, which did not qualitatively affect the results reported.
###end p 74
###begin title 75
Quantitative PCR
###end title 75
###begin p 76
###xml 234 242 234 242 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0001226.s010">File S10</xref>
###xml 540 545 536 541 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Rpl32</italic>
The level of mRNA for each gene was measured with SYBR-Green-based real-time PCR. The primers used for real-time PCR were designed by using Primer Express (Applied Biosystems, Foster City, CA). The primer sequences used are listed in File S10. Each cDNA sample (7 microl) was amplified by using SYBR Green PCR Master Mix according to the manufacturer's instructions. The PCR products and their dissociation curves were detected with the 7500 Fast Real-Time PCR System (Applied Biosystems). The level of the housekeeping gene Ribosomal gene Rpl32 (L32) in each sample was used as an internal control.
###end p 76
###begin title 77
Western Blotting
###end title 77
###begin p 78
Cells were lysed with M-PER Mammalian Protein Extraction Reagent (Pierce, Rockford, IL). Lysates were cleared by centrifugation and protein concentrations were quantified with 1X Quick Start Bradford Dye Reagent (Bio-Rad Laboratories, Hercules, CA) so that equal amounts of protein (40 microg) could be resolved on 10% SDS-polyacrylamide gels. After transfer to membranes, samples were processed and visualized with ECL Western Blotting Reagents (Amersham Biosciences, Piscataway, NJ). All of the Western blotting data shown in this study are representative of at least three independent experiments.
###end p 78
###begin title 79
Anchorage-Independent Growth Assay
###end title 79
###begin p 80
###xml 218 219 218 219 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sup>
A bottom layer of agar was prepared in 60-mm wells by using 3 ml of 1% low melting temperature agarose in normal growth medium. Next, 3 ml of 0.5% low melting temperature agarose in normal growth medium containing 1x105 cells was added on top of the solidified bottom layer. Every 3 days, 5 microg of EphA2-Fc dissolved in normal growth medium was added to each plate. Colonies showing anchorage-independent growth were counted 10-30 days later.
###end p 80
###begin title 81
Cell Viability Assay
###end title 81
###begin p 82
Cell viability was measured with CCK-8 (Dojindo Molecular Technologies, Gaithersburg, MD) according to the manufacturer's protocol, in 96-well plates (seeding density, 5,000 cells per well) at 3 days after treatment with 5 microg/ml of EphA2-Fc or 0.5 microM and 1.0 microM of celecoxib.
###end p 82
###begin title 83
Supporting Information
###end title 83
###begin p 84
Comparison of Gene Expression in EGFR-mutant and -wild-type NSCLC Cells. Genes listed were increased or decreased in EGFR-mutant NSCLC cell lines (n = 4) relative to that of EGFR wild-type cell lines (n = 3).
###end p 84
###begin p 85
(0.06 MB XLS)
###end p 85
###begin p 86
Click here for additional data file.
###end p 86
###begin p 87
Quantitative PCR Analysis of Selected Genes that were Differentially Expressed Based on Expression Profiling of EGFR-mutant and -wild-type NSCLC Cell Lines. Results normalized based on L32 ribosomal RNA expression.
###end p 87
###begin p 88
(0.07 MB DOC)
###end p 88
###begin p 89
Click here for additional data file.
###end p 89
###begin p 90
Mutant EGFR expression profile includes genes with diverse functions. Differentially expressed genes were grouped based on their Gene Ontology functions and represented in a pie chart to illustrate their relative abundance.
###end p 90
###begin p 91
(0.07 MB TIF)
###end p 91
###begin p 92
Click here for additional data file.
###end p 92
###begin p 93
Mutant EGFR expression profile includes genes with diverse functions. Differentially expressed genes are listed according to their Gene Ontology functions.
###end p 93
###begin p 94
(0.43 MB XLS)
###end p 94
###begin p 95
Click here for additional data file.
###end p 95
###begin p 96
Comparison of gene expression in EGFR L858R versus del746-750 NSCLC Cells. Genes listed were increased or decreased in EGFR L858R NSCLC cell lines (n = 2) relative to that of EGFR del746-750 cell lines (n = 3).
###end p 96
###begin p 97
(0.08 MB XLS)
###end p 97
###begin p 98
Click here for additional data file.
###end p 98
###begin p 99
Quantitative PCR analysis of selected genes that were differentially expressed in EGFR L858R and &#xF044;746-750 NSCLC Cell Lines. Results normalized based on L32 ribosomal RNA expression.
###end p 99
###begin p 100
(0.08 MB DOC)
###end p 100
###begin p 101
Click here for additional data file.
###end p 101
###begin p 102
Gene Ontology terms enriched in NSCLC cell lines with EGFR L858R and del746-750.
###end p 102
###begin p 103
(0.50 MB XLS)
###end p 103
###begin p 104
Click here for additional data file.
###end p 104
###begin p 105
Comparison of gefitinib-induced gene expression changes in TKI-sensitive and -resistant EGFR-mutant NSCLC cell lines. The fold difference was calculated by log2[Gefitinib-induced change in expression in sensitive cells (HCC827, H3255, H4006)/resistant cells (H1975)].
###end p 105
###begin p 106
(0.03 MB XLS)
###end p 106
###begin p 107
Click here for additional data file.
###end p 107
###begin p 108
Quantitative PCR analysis of selected genes that were regulated by gefitinib treatment in TKI-sensitive NSCLC cells
###end p 108
###begin p 109
(0.09 MB DOC)
###end p 109
###begin p 110
Click here for additional data file.
###end p 110
###begin p 111
Primers used for quantitative PCR
###end p 111
###begin p 112
(0.03 MB XLS)
###end p 112
###begin p 113
Click here for additional data file.
###end p 113
###begin p 114
We thank Fang Liu for technical assistance with the expression analysis.
###end p 114
###begin title 115
References
###end title 115
###begin article-title 116
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.
###end article-title 116
###begin article-title 117
EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.
###end article-title 117
###begin article-title 118
EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib.
###end article-title 118
###begin article-title 119
###xml 32 36 <span type="species:ncbi:10090">mice</span>
###xml 70 75 <span type="species:ncbi:9606">human</span>
Lung adenocarcinomas induced in mice by mutant EGF receptors found in human lung cancers respond to a tyrosine kinase inhibitor or to down-regulation of the receptors.
###end article-title 119
###begin article-title 120
###xml 14 19 <span type="species:ncbi:9606">human</span>
The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies.
###end article-title 120
###begin article-title 121
###xml 152 157 <span type="species:ncbi:9606">human</span>
Multiple oncogenic changes (K-RAS(V12), p53 knockdown, mutant EGFRs, p16 bypass, telomerase) are not sufficient to confer a full malignant phenotype on human bronchial epithelial cells.
###end article-title 121
###begin article-title 122
Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways.
###end article-title 122
###begin article-title 123
High expression of ErbB family members and their ligands in lung adenocarcinomas that are sensitive to inhibition of epidermal growth factor receptor.
###end article-title 123
###begin article-title 124
Kinetic analysis of epidermal growth factor receptor somatic mutant proteins shows increased sensitivity to the epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib.
###end article-title 124
###begin article-title 125
Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants.
###end article-title 125
###begin article-title 126
Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity.
###end article-title 126
###begin article-title 127
ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines. Proc.Natl.Acad.Sci.U.S.A.
###end article-title 127
###begin article-title 128
Dasatinib (BMS-354825) selectively induces apoptosis in lung cancer cells dependent on epidermal growth factor receptor signaling for survival.
###end article-title 128
###begin article-title 129
SRC-family kinases are activated in non-small cell lung cancer and promote the survival of epidermal growth factor receptor-dependent cell lines.
###end article-title 129
###begin article-title 130
###xml 45 53 <span type="species:ncbi:9606">patients</span>
Gene-expression profiles predict survival of patients with lung adenocarcinoma.
###end article-title 130
###begin article-title 131
###xml 18 23 <span type="species:ncbi:9606">human</span>
Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses.
###end article-title 131
###begin article-title 132
Update on epidermal growth factor receptor mutations in non-small cell lung cancer.
###end article-title 132
###begin article-title 133
###xml 187 192 <span type="species:ncbi:9606">human</span>
Activation of mitogen-activated protein kinase in estrogen receptor alpha-positive breast cancer cells in vitro induces an in vivo molecular phenotype of estrogen receptor alpha-negative human breast tumors.
###end article-title 133
###begin article-title 134
###xml 27 32 <span type="species:ncbi:9606">human</span>
Probabilistic model of the human protein-protein interaction network.
###end article-title 134
###begin article-title 135
Lethality and centrality in protein networks Nature
###end article-title 135
###begin article-title 136
The role of cyclooxygenases in inflammation, cancer, and development.
###end article-title 136
###begin article-title 137
###xml 19 27 <span type="species:ncbi:9606">patients</span>
Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib.
###end article-title 137
###begin article-title 138
Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers.
###end article-title 138
###begin article-title 139
Differential regulation of EphA2 in normal and malignant cells.
###end article-title 139
###begin article-title 140
A conditional feedback loop regulates Ras activity through EphA2.
###end article-title 140
###begin article-title 141
Soluble Eph A receptors inhibit tumor angiogenesis and progression in vivo.
###end article-title 141
###begin article-title 142
###xml 71 76 <span type="species:ncbi:9606">Human</span>
EGFR Signaling is Required for TGF-{beta}1-mediated COX-2 Induction in Human Bronchial Epithelial Cells.
###end article-title 142
###begin article-title 143
Epidermal growth factor-induced cyclooxygenase-2 expression is mediated through phosphatidylinositol-3 kinase, not mitogen-activated protein/extracellular signal-regulated kinase kinase, in recurrent respiratory papillomas.
###end article-title 143
###begin article-title 144
MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling.
###end article-title 144
###begin article-title 145
Regulatory roles for MD-2 and TLR4 in ligand-induced receptor clustering.
###end article-title 145
###begin article-title 146
Fractalkine mediates natural killer-dependent antitumor responses in vivo.
###end article-title 146
###begin article-title 147
###xml 54 59 <span type="species:ncbi:9606">human</span>
Interferon-gamma stimulates fractalkine expression in human bronchial epithelial cells and regulates mononuclear cell adherence.
###end article-title 147
###begin article-title 148
###xml 109 114 <span type="species:ncbi:9606">human</span>
CX3CR1-fractalkine expression regulates cellular mechanisms involved in adhesion, migration, and survival of human prostate cancer cells.
###end article-title 148
###begin article-title 149
###xml 77 82 <span type="species:ncbi:9606">human</span>
###xml 119 123 <span type="species:ncbi:10090">mice</span>
Profiling of pathway-specific changes in gene expression following growth of human cancer cell lines transplanted into mice.
###end article-title 149
###begin article-title 150
Statistical significance for genomewide studies.
###end article-title 150
###begin article-title 151
The database of interacting proteins:2004 update.
###end article-title 151
###begin article-title 152
Cluster analysis and display of genome-wide expression patterns.
###end article-title 152
###begin article-title 153
Java Treeview-extensible visualization of microarray data.
###end article-title 153
###begin p 154
###xml 0 21 0 21 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Competing Interests: </bold>
Competing Interests: The authors have declared that no competing interests exist.
###end p 154
###begin p 155
###xml 0 9 0 9 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Funding: </bold>
Funding: This work was supported by National Cancer Institute grants P50 CA70907, P30 CA125123, and R01 CA117965.
###end p 155

